Summary
This document is an executive summary detailing GSK's Collaborative Working initiative aimed at improving equitable access to National Adult Immunisation Programmes in the UK. The project, set to run from June 2024 to December 2025, focuses on enhancing vaccination delivery for shingles and pneumococcal diseases, particularly in areas with lower than average uptake and higher deprivation levels. GSK will collaborate with NHS organisations to identify priority areas and provide non-clinical staff to assist in patient identification and recall processes. The document outlines primary project objectives, including reducing health inequalities and increasing vaccination uptake in line with national eligibility criteria. Additionally, it describes intended benefits for patients, NHS organisations, and GSK, such as improved health outcomes, reduced administrative burdens, and enhanced capability for implementing immunisation programmes. Reports on project outcomes will be published on the GSK UK website following project completion.
